News & Updates

In the phase III ICONIC-LEAD trial, selective blockade of the interleukin(IL)-23 receptor with the targeted oral peptide icotrokinra is associated with higher rates of skin clearance and symptom relief in adults and adolescents with moderate-to-severe plaque psoriasis.

The fatty acid synthase inhibitor denifanstat shows potential for treating moderate-to-severe acne vulgaris, with good safety and tolerability, as demonstrated in a study from China presented at EADV 2025.

The final, long-term results from the phase III CheckMate 238 trial continue to show the superior recurrence-free survival (RFS) benefit of adjuvant nivolumab (NIVO) over ipilimumab (IPI) for resected stage IIIB-C or IV melanoma.